Literature DB >> 24442858

Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experience.

Wolfgang Füreder1, Andrea Paulitsch-Buckingham, Werner Rabitsch, Eva Jäger, Ilse Schwarzinger, Wolfgang R Sperr, Peter Valent.   

Abstract

We analyzed the clinical course and outcome in 50 patients (27 males, 23 females) suffering from aplastic anemia (AA), treated in our department between 1987 and 2007. The median age was 37 years (range: 14-70 years). A total of 42 patients received antithymocyte globulin and cyclosporine A (CSA). Seven patients were transplanted using a matched sibling donor upfront, and one patient was treated with CSA and growth factors only. A total of 34 patients (68 %) achieved a complete remission, and 7 (14 %), a partial remission. Eight patients (16 %) did not respond to treatment, and one died shortly after transplantation. Relapses of AA occurred in eight patients (20 %). No obvious correlations between clinical parameters, including age, karyotype, existence of paroxysmal nocturnal hemoglobinuria clones, pretreatment blood counts, progenitor cell counts, and the response to immunosuppressive therapy (IST), were found. We also examined the numbers of colony-forming progenitor cells (CFUs) before and after therapy. In most responding patients, CFU numbers increased substantially after successful therapy. However, even in patients without a substantial increase in CFU, stable remissions were observed. Together, both IST and stem cell transplantation are reasonable treatment options for patients with AA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24442858     DOI: 10.1007/s00508-013-0484-2

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  24 in total

1.  Abnormalities of hematopoietic progenitor cells in patients with aplastic anemia after hematologic recovery.

Authors:  S Issaragrisil; A Piankijagum; Y Tang-Naitrisorana
Journal:  J Med Assoc Thai       Date:  1989-11

2.  Criteria for severe aplastic anaemia.

Authors:  B M Camitta
Journal:  Lancet       Date:  1988-02-06       Impact factor: 79.321

3.  Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia.

Authors:  Chiharu Sugimori; Tatsuya Chuhjo; Xingmin Feng; Hirohito Yamazaki; Akiyoshi Takami; Masanao Teramura; Hideaki Mizoguchi; Mitsuhiro Omine; Shinji Nakao
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

4.  Lack of in vitro colony (CFUC) formation and myelosuppressive activity in patients with severe aplastic anemia after autologous hematologic reconstitution.

Authors:  A Bacigalupo; M Podesta'; M R Raffo; G Piaggio; M T Van Lint; R Vimercati; V M Spriano; M Risso; A M Marmont
Journal:  Exp Hematol       Date:  1980-07       Impact factor: 3.084

5.  Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival.

Authors:  Monika Führer; Udo Rampf; Irith Baumann; Andreas Faldum; Charlotte Niemeyer; Gritta Janka-Schaub; Wilhelm Friedrich; Wolfram Ebell; Arndt Borkhardt; Christine Bender-Goetze
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

6.  Interleukin-10 inhibits spontaneous colony-forming unit-granulocyte-macrophage growth from human peripheral blood mononuclear cells by suppression of endogenous granulocyte-macrophage colony-stimulating factor release.

Authors:  L Oehler; M Foedinger; M Koeller; M Kollars; E Reiter; B Bohle; S Skoupy; G Fritsch; K Lechner; K Geissler
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

Review 7.  Hematopoietic progenitor cells in the blood and bone marrow in various hematologic disorders.

Authors:  S Issaragrisil; Y U-pratya; M Yimyam; K Pakdeesuwan; A Khuhapinant; W Muangsup; K Pattanapanyasat
Journal:  Stem Cells       Date:  1998       Impact factor: 6.277

8.  Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia.

Authors:  Jaroslaw P Maciejewski; Antonio Risitano; Elaine M Sloand; Olga Nunez; Neal S Young
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

9.  Colony growth characteristics in chronic myelomonocytic leukemia.

Authors:  K Geissler; W Hinterberger; P Bettelheim; O Haas; K Lechner
Journal:  Leuk Res       Date:  1988       Impact factor: 3.156

10.  Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.

Authors:  Norbert Frickhofen; Hermann Heimpel; Joachim P Kaltwasser; Hubert Schrezenmeier
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113

View more
  3 in total

1.  I walk the line: how to tell MDS from other bone marrow failure conditions.

Authors:  Lukasz P Gondek; Amy E DeZern
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 2.  The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure.

Authors:  Amy E DeZern; Mikkael A Sekeres
Journal:  Oncologist       Date:  2014-06-04

3.  Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm.

Authors:  Wolfgang Füreder; Sabine Cerny-Reiterer; Wolfgang R Sperr; Leonhard Müllauer; Eva Jäger; Ilse Schwarzinger; Klaus Geissler; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2016-10-14       Impact factor: 1.704

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.